PubMed Health⌕ Search

PubMed · 10598159

[Systemic mastocytosis].

Abstract

UNLABELLED: HEMATOPOIESIS DISORDER: Systemic mastocytosis is a primary proliferation of mast cells in several noncutaneous tissues. It remains an uncommon disease, difficult to diagnosis and often missed. The spectrum of clinical signs is wide and the course and prognosis are quite variable. CLINICAL ASPECTS: Sudden release of mediators by mast cell degranulation lead manifestations of paroxysmal congestion. Pigmentary urticaria is the most frequent cutaneous form. Among visceral localizations, bone involvement is encountered in 90% of the cases, digestive tract and hematological involvement are less frequent. Respiratory and cardiovascular involvement is exceptional. DIAGNOSIS: Osteomedullary biopsy is required for diagnosis. Urinary histamine metabolites may be suggestive. PROGNOSIS: Prognosis depends on the presence of an associated hematological disorder, found in 30% of the cases. TREATMENT: Symptomatic treatment is the rule, aimed at blocking histamine release by mast cell degranulation and avoid the subsequent paroxysmal manifestations.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Duché. 1999-11-13. [Systemic mastocytosis].. https://pubmed.ncbi.nlm.nih.gov/10598159/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Does potency predict clinical efficacy? Illustration through an antihistamine model.

OBJECTIVE: The concepts of potency and efficacy are often confused and used interchangeably within the scientific and pharmaceutical industry. It is important that the distinction between the two is understood, and that the terms are defined within their correct context. After reading this article, readers should have an understanding of the relationships between receptor potency and clinical efficacy. DATA SOURCES: Following a comprehensive review of the literature using MEDLINE, the author observed a lack of relevant references that relate measurements of potency to clinical efficacy. Therefore, the author reviewed the basic pharmacologic principles of potency using examples from the recent antihistamine literature. RESULTS: Potency is an expression of the activity of a drug in terms of the concentration or amount of the drug required to produce a defined effect, whereas clinical efficacy judges the therapeutic effectiveness of the drug in humans. The differing methods of evaluating the activity of antihistamines in vitro and in vivo can lead to inconsistent results, which complicate the use of potency to predict clinical efficacy. Further, as therapeutic behavior is modulated by pharmacokinetic and pharmacodynamic parameters and by further interactions at sites other than the target receptor, it does not necessarily follow that more potent drugs have greater clinical efficacy. CONCLUSIONS: Although potency can be a good preclinical marker of the therapeutic potential of a drug, clinical efficacy should only be evaluated within the patient population using appropriate outcome measures.

Histamine Antagonists↗